Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 361Precursor Cell Lymphoblastic Leukemia-Lymphoma 328Lymphoma 297Leukemia 254Multiple Myeloma 246Leukemia, Myeloid, Acute 241Lymphoma, Non-Hodgkin 240Lymphoma, Large B-Cell, Diffuse 238Leukemia, Lymphocytic, Chronic, B-Cell 220Myelodysplastic Syndromes 184Lymphoma, Follicular 176Hodgkin Disease 165Lymphoma, Mantle-Cell 163Burkitt Lymphoma 160Lymphoma, B-Cell, Marginal Zone 117Recurrence 115Lymphoma, Large-Cell, Immunoblastic 95Leukemia, Myelogenous, Chronic, BCR-ABL Positive 82Myeloproliferative Disorders 81Melanoma 78Neoplasms, Plasma Cell 77Leukemia, Myeloid, Chronic-Phase 72Hematologic Neoplasms 72Leukemia, Myeloid, Accelerated Phase 71Leukemia, Myelomonocytic, Chronic 69Lymphoma, B-Cell 65Dendritic Cell Sarcoma, Interdigitating 64Triple Negative Breast Neoplasms 63Ovarian Neoplasms 61Congenital Abnormalities 59

Interventions

Interleukin-2 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Invasive Bladder Cancer Stage IV × Cyclophosphamide × Clear all
NCT02863913 2019-03-06

PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer

Peking University

Phase 1 Withdrawn
Genitourinary

Invasive Bladder Cancer Stage IV

Data powered by HemOnc (CC BY 4.0) Colophon âš¡